article Open AccessTop 1% cited

Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease

Annals of Neurology · 2015 · Vol. 79(1) · pp. 110–119

Keith A. Johnson✉(Harvard University)Aaron P. Schultz(Athinoula A. Martinos Center for Biomedical Imaging)Rebecca A. Betensky(Massachusetts General Hospital)J. Alex Becker(Massachusetts General Hospital)Jorge Sepulcre(Harvard University)Dorene M. Rentz(Brigham and Women's Hospital)Elizabeth C. Mormino(Boston University)Jasmeer P. Chhatwal(Harvard University)Rebecca E. Amariglio(Boston University)Kathryn V. Papp(Boston Medical Center)Gad A. Marshall(Boston Medical Center)Mark W. Albers(Boston Medical Center)Samantha Mauro(Massachusetts General Hospital)Lesley Pepin(Society of Nuclear Medicine and Molecular Imaging)Jonathan Alverio(Massachusetts General Hospital)Kelly Judge(Society of Nuclear Medicine and Molecular Imaging)Marlie Philiossaint(Massachusetts General Hospital)Timothy M. Shoup(Society of Nuclear Medicine and Molecular Imaging)Daniel Yokell(Harvard University)Bradford C. Dickerson(Boston Medical Center)Teresa Gómez‐Isla(Harvard University)Bradley T. Hyman(Harvard University)Neil Vasdev(Society of Nuclear Medicine and Molecular Imaging)Reisa A. Sperling(Harvard University)

View via DOI Full-text PDF

Abstract

These findings suggest that (18)F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Functional Brain Connectivity StudiesTauopathyNeuropathologyPositron emission tomographyDementiaPittsburgh compound BBiomarkerNeuroscienceMedicineDiseasePsychology

MeSH terms

AgedAged, 80 and overAgingAlzheimer DiseaseAniline CompoundsCarbolinesCerebral CortexFemaleHumansMaleMiddle AgedTemporal LobeThiazolesBiomarkersAmyloid beta-Peptides